Posted by Michael Wonder on 21 Jan 2021
FDA grants priority review to Genentech’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease
21 January 2021 - Genentech announced today that the U.S. FDA has accepted the company’s supplemental new drug application and granted priority review for Esbriet (pirfenidone) for the treatment of unclassifiable interstitial lung disease.
The FDA is expected to make a decision on approval by May 2021.
